Recombinant Anti-Fluorescein (Clone 4-4-20 (enhanced))
| Conjugation | Unconjugated |
| Modifications | This is a chimeric human antibody, based on the original mouse IgG2a format, created for improved compatibility with existing reagents, assays and techniques. |
Recombinant Anti-erbB-2 (Her-2/neu) (Clone 4D5-8 (trastuzumab))
| Applications | ELISA, FC, IHC |
| Reactivities | Human |
| Conjugation | Unconjugated |
| Modifications | NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. |
Recombinant Anti-CD20 (Clone 10F381 (rituximab))
| Applications | FC |
| Reactivities | Human, Monkey |
| Conjugation | Unconjugated |
| Modifications | NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. |
Recombinant Anti-TNF alpha (Clone cA2 (Infliximab))
| Applications | ELISA, FC |
| Reactivities | Human |
| Conjugation | Unconjugated |
| Modifications | NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This is a chimeric antibody created for improved compatibility with existing reagents, assays and techniques. |
Recombinant Anti-TRP-1, gp75 (Clone TA99)
| Applications | ELISA, FC, IF, IHC, IP, WB |
| Reactivities | Human |
| Conjugation | Unconjugated |
| Modifications | This chimeric human antibody was made using the variable domain sequences of the original Mouse IgG2a format, for improved compatibility with existing reagents, assays and techniques. |
USD 523.00
2 Weeks
USD 523.00
2 Weeks
Recombinant Anti-IL-2R alpha (CD25) (Clone Basiliximab)
| Applications | FC, IF, IHC, WB |
| Reactivities | Human, Monkey |
| Conjugation | Unconjugated |
| Modifications | NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This is a chimeric antibody created for improved compatibility with existing reagents, assays and techniques. |
Recombinant Anti-CD41 (Clone 7E3 (Abciximab))
| Applications | FC |
| Reactivities | Human |
| Conjugation | Unconjugated |
| Modifications | This is a reformatted human IgG1 antibody based on the therapeutic Fab fragment. NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. |
Recombinant Anti-Human Ephrin Type A receptor 2 (Clone 1C1)
| Applications | ELISA, FC, IF, WB |
| Reactivities | Human |
| Conjugation | Unconjugated |
Recombinant Anti-CD40L (Clone hu5c8 (Ruplizumab))
| Applications | FC, WB |
| Reactivities | Human |
| Conjugation | Unconjugated |
| Modifications | NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. |
Recombinant Anti-CD11a (Clone hu1124 (Efalizumab))
| Applications | FC |
| Reactivities | Human |
| Conjugation | Unconjugated |
Recombinant Anti-OX40L (Clone R4930 (Oxelumab))
| Applications | FC |
| Reactivities | Human |
| Conjugation | Unconjugated |
Recombinant Anti-ED-B domain of fibronectin (Clone A2)
| Applications | ELISA, IHC, WB |
| Reactivities | Human |
| Conjugation | Unconjugated |
| Modifications | This full-length, reformatted human antibody was made using the variable domain sequences of the original Human scFv format, for improved compatibility with existing reagents, assays and techniques. |
Recombinant Anti-ED-B domain of fibronectin (Clone G4)
| Applications | ELISA, IHC, WB |
| Reactivities | Human |
| Conjugation | Unconjugated |
| Modifications | This full-length, reformatted human antibody was made using the variable domain sequences of the original Human scFv format, for improved compatibility with existing reagents, assays and techniques. |
Recombinant Anti-VEGF (Clone Bevacizumab)
| Applications | ELISA, FC, IP, WB |
| Reactivities | Human |
| Conjugation | Unconjugated |
| Modifications | NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. |
Recombinant Anti-TNF alpha (Clone D2E7 (Adalimumab))
| Applications | ELISA, IF, IHC |
| Reactivities | Human |
| Conjugation | Unconjugated |
| Modifications | NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. |
Recombinant Anti-EGFR domain III (Clone h-R3 (Nimotuzumab))
| Applications | FC, IHC |
| Reactivities | Human |
| Conjugation | Unconjugated |
Recombinant Anti-CD22 (Clone hL22 (Epratuzumab))
| Applications | Bl, FC, IP |
| Reactivities | Human, Monkey |
| Conjugation | Unconjugated |
Recombinant Anti-RSV (Clone RSHZ19 (Felvizumab))
| Applications | ELISA |
| Reactivities | Respiratory Syncytial Virus |
| Conjugation | Unconjugated |
Recombinant Anti-CD64 (Clone H22)
| Applications | FC |
| Reactivities | Human |
| Conjugation | Unconjugated |
| Modifications | This chimeric human antibody was made using the variable domain sequences of the original IgG1 format, for improved compatibility with existing reagents, assays and techniques. |
Recombinant Anti-IL-6 receptor (Clone rhPM-1 (Tocilizumab))
| Applications | ELISA |
| Reactivities | Human |
| Conjugation | Unconjugated |
| Modifications | NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. |
Recombinant Anti-Fas (Clone R-125224)
| Applications | ELISA, FC |
| Reactivities | Human |
| Conjugation | Unconjugated |
USD 523.00
2 Weeks
Recombinant Anti-EGFR (Clone 2F8 (Zalutumumab; HuMax-EGFR))
| Applications | ELISA, FC, WB |
| Reactivities | Human |
| Conjugation | Unconjugated |
Recombinant Anti-COVID-19 & SARS-CoV S glycoprotein (Clone CR3022)
| Applications | ELISA, IF |
| Conjugation | Unconjugated |
USD 523.00
2 Weeks
Recombinant Anti-Covid-19 & SARS-CoV Nucleoprotein (Clone CR3018 (03-018))
| Applications | ELISA, IF |
| Reactivities | SARS-CoV |
| Conjugation | Unconjugated |
USD 523.00
2 Weeks
Recombinant Anti-Covid-19 & SARS-CoV Nucleoprotein (Clone CR3009 (03-009))
| Applications | ELISA, IF |
| Reactivities | SARS-CoV |
| Conjugation | Unconjugated |
Recombinant Anti-PD-L1 (Clone 332M7)
| Applications | FC |
| Reactivities | Human, Monkey, Mouse |
| Conjugation | Unconjugated |
Germany
Japan
United Kingdom
China
